Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
तुलना करने के लिए मीट्रिक्स | NVAX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNVAXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 4.1x | −3.0x | −0.5x | |
PEG अनुपात | 0.02 | −0.02 | 0.00 | |
क़ीमत/बुक | −9.0x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.3x | 8.2x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 26.9% | 176.8% | 46.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.9% | 5.4% | अनलॉक करें |